SUBSCRIBE
SUBSCRIBE

Aimmune Therapeutics

NEWS
Bay Area Startup Arcus Biosciences Lands $307 Million+ Deal With Taiho Pharma
Biotech Bay
Bay Area’s Aimmune Gets $145 Million Infusion From Nestlé Health Science
November 4, 2016
 · 
2 min read
Here’s Why 5 Billionaire-Led Funds Gobbled Up 3.3 Million Shares of Celldex Stock
Bio NC
4 Biotech Stocks That Could Triple In Value This Year
August 4, 2016
 · 
2 min read
Astellas Pharma, Proteostasis Therapeutics Forge $1.2 Billion Genetic Disease Drug Development Pact
Job Trends
NorCal’s Aimmune Signs Lease for Huge Facility in Florida
August 11, 2015
 · 
2 min read
Astellas Pharma, Proteostasis Therapeutics Forge $1.2 Billion Genetic Disease Drug Development Pact
Deals
Bay Area’s Global Blood Therapeutics, Aimmune Jump on the IPO Wagon Seeking $115 Million Each
July 10, 2015
 · 
3 min read
Load More
AWARDS
  • 2022 Best Places to Work
JOBS
IN THE PRESS
Biotech Bay
Aimmune to Present New Clinical Data at AAAAI Annual Meeting
February 25, 2020
 · 
10 min read
Biotech Bay
Aimmune Therapeutics to Host Conference Call and Webcast to Discuss Fourth Quarter and Full-Year 2019 Financial Results and Recent Operational Highlights
February 20, 2020
 · 
1 min read
Biotech Beach
Aimmune Licenses Exclusive Worldwide Rights to Xencor’s XmAb®7195 for the Development of Next-Generation Food Allergy Treatments
February 5, 2020
 · 
5 min read
Biotech Bay
Aimmune Therapeutics Announces Additional $200 Million Equity Investment by Nestlé Health Science
February 5, 2020
 · 
10 min read
FDA
FDA Approves Aimmune’s PALFORZIA™ as First Treatment for Peanut Allergy
January 31, 2020
 · 
14 min read
Biotech Bay
Aimmune Therapeutics to Present at the 38th Annual J.P. Morgan Healthcare Conference
January 6, 2020
 · 
1 min read
Biotech Bay
Aimmune to Participate in Three Upcoming Investor Conferences
November 15, 2019
 · 
2 min read
Job Trends
New Real-World Data Unveiled at ACAAI Indicates Comparable Clinical Practice Logistics to Implement Oral Immunotherapy and Environmental Allergy Shots
November 8, 2019
 · 
6 min read
Drug Development
AR101 Demonstrates Consistent Efficacy and Safety in New Analysis at ACAAI Comparing PALISADE and ARTEMIS Phase 3 Clinical Data
November 8, 2019
 · 
8 min read
Business
Aimmune Therapeutics Announces Third Quarter 2019 Financial Results and Provides Operational Highlights
November 6, 2019
 · 
12 min read
Load More